Quote:Sapigen Biologix plant in Odisha to lead India’s vaccine production with May inauguration

The first-ever vaccine plant in Odisha, Sapigen Biologix, is preparing for commercial production, which is expected to start in May of this year. Situated in the Biotech Park in Andharua, close to Bhubaneswar, this facility is well-positioned to become a major player in the vaccine manufacturing industry, with an astounding daily capacity of Rs 2.4 crore doses for a variety of vaccines.

... With a Rs 1,500 crore investment, the ambitious project represents a significant advancement in strengthening India’s capacity to manufacture vaccines.

The factory wants to produce a wide variety of vaccinations in order to support global health initiatives, rather than just focus on scale. Aiming to produce more than 15 vaccinations that target a range of diseases, such as malaria and cholera, the facility hopes to have a significant impact on public health.

The plant is expected to be a major source of economic growth in the area in addition to its function in healthcare. According to the CMO, 1,500 people are anticipated to get direct employment prospects from the factory, with a focus on hiring locals. This action supports more general objectives of promoting regional economic growth and supplying sustainable means of subsistence.

...

Quote:Odisha Sets June 2022 Target For Covaxin Production At Andharua Unit
By OB Bureau On May 6, 2021

Bhubaneswar: Construction of vaccine production unit has started at Andharua in the capital city and a target has been set to commence production of Covaxin by June, 2022.

...
The Andharua anchor vaccine unit being set up through Bharat Biotech International Ltd (BBIL, will produce around 10 types of advanced vaccines including that for corona and malaria, stated a release.
...
Secretary, Science and Technology, Manoj Mishra said around Rs 15 crore was allocated under the ‘Fund of Funds’ of MSME department for providing equity support to the incubating units in Biotechnology sector.